Biologic Activity of Tamoxifen at Low Doses in Healthy Women

Abstract

Tamoxifen is an estrogen receptor modulator with proven efficacy in reducing breast cancer recurrence and mortality following surgery in patients with estrogen receptor-positive tumors (1). A significant reduction in contralateral breast cancer is observed in most trials of adjuvant treatment (1), which has further provided a rationale to assess the efficacy of tamoxifen as a primary preventive agent for women at risk of developing breast cancer (2).